A recent study shows that genetic variants linked to Type 2 Diabetes (T2D) can predict poorer outcomes in metastatic colon cancer (mCC), even in patients without diabetes. Researchers analyzed 15 T2D-associated genes in 99 non-diabetic mCC patients over a median follow-up of 42 months.
Two variants were particularly impactful: CDKN1B p.V109G carriers had a median overall survival (mOS) of 45 months versus 87 months for those without the mutation, representing a 2.13-fold higher death risk. TCF7L2 p.P370R carriers fared worse, with mOS of 19.8 months versus 61.6 months, corresponding to an 8.13-fold increased risk. Patients with more than three T2D-related variants also experienced significantly shorter survival, suggesting cumulative effects.
Both genes are biologically relevant: CDKN1B regulates cell growth, and TCF7L2 is critical in Wnt signaling. These findings were independent of age, gender, metastasis extent, tumor mutations, and treatment response, highlighting a new genetic-based approach for risk assessment and personalized therapy in metastatic colon cancer.